Home » Retrophin’s RE-024 Gains EU Orphan Drug Status
Retrophin’s RE-024 Gains EU Orphan Drug Status
Retrophin has won EU orphan drug status for RE-024, a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration.
The FDA also awarded the candidate orphan drug designation for the same indication, as well as fast track status.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct